Literature DB >> 6426006

Immunologically generated circulating anticoagulants in humans.

R L Edwards, C J Wakem.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6426006     DOI： 10.1007/bf02918599

Source DB:  PubMed          Journal:  Surv Immunol Res        ISSN： 0252-9564


× No keyword cloud information.
  14 in total

1.  On the characterization of acquired inhibitors to ristocetin induced platelet aggregation found in patients with von Willebrand's disease.

Authors:  N Egberg; M Blombäck
Journal:  Thromb Res       Date:  1976-11       Impact factor: 3.944

2.  Immunosuppressive therapy of Factor VIII inhibitors.

Authors:  M B Hultin; S S Shapiro; H S Bowman; F M Gill; A T Andrews; J Martinez; E M Eyster; W C Sherwood
Journal:  Blood       Date:  1976-07       Impact factor: 22.113

Review 3.  Hemostatic abnormalities associated with dysproteinemias.

Authors:  H Lackner
Journal:  Semin Hematol       Date:  1973-04       Impact factor: 3.851

4.  The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors.

Authors:  M W Hilgartner; G L Knatterud
Journal:  Blood       Date:  1983-01       Impact factor: 22.113

5.  Heterogeneity of factor VIII antibodies: further immunochemical and biologic studies.

Authors:  M B Hultin; F S London; S S Shapiro; W J Yount
Journal:  Blood       Date:  1977-05       Impact factor: 22.113

Review 6.  Factor VIII inhibitors: a clinical overview.

Authors:  G C White; C W McMillan; P M Blatt; H R Roberts
Journal:  Am J Hematol       Date:  1982-12       Impact factor: 10.047

7.  Successful management of bleeding in a patient with factor V inhibitor by platelet transfusions.

Authors:  J Chediak; J B Ashenhurst; I Garlick; R K Desser
Journal:  Blood       Date:  1980-11       Impact factor: 22.113

8.  Thrombosis in patients with the lupus anticoagulant.

Authors:  J R Mueh; K D Herbst; S I Rapaport
Journal:  Ann Intern Med       Date:  1980-02       Impact factor: 25.391

9.  Chlorpromazine-induced lupus anticoagulant and associated immunologic abnormalities.

Authors:  R T Canoso; H S Sise
Journal:  Am J Hematol       Date:  1982-09       Impact factor: 10.047

10.  Inactivation of factor VIII coagulant activity by two different types of human antibodies.

Authors:  M S Gawryl; L W Hoyer
Journal:  Blood       Date:  1982-11       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.